SPECT in the Evaluation of Brain Tumors

journal or publication title	SPECT: Technology, Procedures and Applications
year	2013
URL	http://hdl.handle.net/2241/00121551

Chapter X: SPECT in the evaluation of brain tumors

Yasushi Shibata, M.D., Ph.D.

Department of Neurosurgery,

Mito Medical Center, University of Tsukuba

Email: yshibata@md.tsukuba.ac.jp

X-1 Brain tumors

A brain tumor is an intracranial neoplasm that has various pathologies (*1*).Using diagnostic information, a tumor can be classified as least aggressive (benign) to most aggressive (malignant). In most cases, a brain tumor is named for the cell type of origin or its location. Identifying the type ofbrain tumor helps to determine the most appropriate course of treatment.

There are three main types of brain tumors: intra-medullary, extra-medullary, and metastatic. Most intra-medullary tumors originate from glial cells and are called gliomas.A glioma is generally infiltrative into the brain parenchyma; therefore, a complete surgical excision is usually difficult. The prognosis of patients with a glioma depends on the malignancy grade of the tumor; although, it is generally poor. On the other hand, most extra-medullary brain tumors are benign and complete surgical removal results in a good prognosis. Metastatic brain tumors are always malignant and although the prognosis depends on a patient's systemic condition, it is generally poor.

X-2 Diagnosis of brain tumors

The main symptoms of brain tumors are headache, paresis, and epileptic seizures. A progressive clinical course suggests a brain tumor. An accurate preoperative diagnosis of the tumor pathology and malignancy grade is often challenging. Most intra-medullary tumors are malignant; however, they may be benign; while, the majority of extra-medullary tumors are benign,but malignant tumors also exist. Selecting an appropriate treatment depends on the malignancy grade and prognosis of the tumor; thus, a correct preoperative diagnosis is important. The final diagnosis depends on the pathological analysis of the surgical specimen.

X-3 Radiological diagnosis of brain tumors

Brain magnetic resonance imaging (MRI) is the modality of choice for evaluating patients who have symptoms and signs suggesting a brain tumor and for assessing the tumor location and extent. Even if most clinical questions can be answered by MRI and computed tomography (CT), these techniques have limitations in the characterization of brain lesions, defining the tumor extent,

therapy monitoring, and in detecting the recurrence or progression of tumors. High contrast enhancement in a tumor means high blood flow but not necessarily malignancy. Meningioma and pituitary adenomas are typical benign extra-medullary tumors with high contrast enhancement. In addition, complete visualization of infiltrating malignant glioma cells is difficult, even with high resolution MRI.

The brain neoplasms are treated with various combinations of surgery, radiation, and chemotherapy. Changes that follow treatment may include edema and radiation necrosis, and it is often challenging to differentiate between tumor recurrence and such benign physical changes with CT or MRI(*2-5*). Nuclear medicine imaging allows *in vivo* investigation of tumor metabolism, given the wide availability of radiotracers, and plays a major role in the diagnosis and follow-up of patients with brain tumors.

X-4 SPECT for the diagnosis and evaluation of brain tumors

Single photon emission computed tomography (SPECT) is a valuable diagnostic modality for the evaluation of the brain tumor malignancy grade and activity.Thallium-201 (Tl) and two Technetium-99m labeled

radiopharmaceuticals (methoxyisobutylisonitrile (Tc-MIBI) and tetrofosmin (TF))have been clinically used with SPECT to evaluate brain tumors. SPECT has also been used with the radioactive labeled amino acid 3-[123I]iodo-a-methyl-L-tyrosine for the diagnosis of brain tumors and evaluation of tumor response to radiation therapy.

X-4-1 TI SPECT

TI, a potassium analog, is taken up by viable tumor cells but not by necrotic tissue or non-proliferating glial cells(*6*).It is cyclotron produced with a physical half-life of 73 hours. TI has been used in myocardial scintigraphy and in evaluating lung carcinomas and brain tumors. TI SPECT is useful for identifying the presence of a tumor (*7*), grading of the tumor malignancy(*3, 4, 6*),and distinguishing tumor recurrence from radiation necrosis (*2-4*)(**Figure 1**).The SPECT procedure involves imaging approximately 20-30 minutes following injection of 74-148 MBq of TI. Occasionally, a 2-hour delayed TI acquisition may be helpful as the abnormal tumor tissue would be expected to washout more slowly than normal brain tissue (*8, 9*).The SPECT imaging should be done using

a low energy general purpose collimator. The photopeak should be centered at 80 and 167 keV. The Tl index, the ratio of counts in the lesion region of interest (ROI) to counts in the contralateral ROI, is used to differentiate between low and high grade gliomas(*6*) as well as between recurrence and radiation necrosis (*11, 12*).The value of these ratios varies according to the identification of the ROI, the location and size of the lesion, and whether or not there is central necrosis. Some investigators recommend drawing the ROI over the highest pixel counts of Tl uptake; while, others recommend drawing it over the inner and outer border of the tumor and averaging the pixel counts. Ratios above 1.6-2.4 may indicate malignant lesions; while, lower ratios indicate either benign lesions or early recurrence (*13*).In a population of 90 patients with supratentorial brain tumors, the overall sensitivity and specificity of Tl in detecting the lesions were 71.7% and 80.9% respectively(*14*).Dynamic Tl SPECT is useful to evaluate tumor vascularity, histopathology, and malignancy (*15, 16*).The utility of Tl SPECT in differentiating toxoplasmosis from lymphoma in AIDS patients was demonstrated by Kessler et al.(*17*) with a sensitivity of 100% and specificity of 93%.

The utility of Tl SPECT as an early predictor of outcome in patients with recurrent gliomas has been shown by Vos et al.They reported that at baseline and follow-up, maximal tumor intensity by Tl SPECT was the strongest predictive variable and was inversely related to overall survival as well as progression-free survival. They also showed a progression of maximal tumor intensity after two courses of chemotherapy was a powerful predictor of poor outcome. For a Tl-avid lesion that has been treated and shown to be Tl negative on follow-up, any Tl uptake is an indicator of tumor recurrence(13).Glioma surgery may improve the prognosis, but this is controversial, possibly due to the method of evaluating glioma surgical extent. In a study from our group, we evaluated the glioma surgical extent using fusion images of preoperative Tl SPECT with postoperative MRI to predict the prognosis of the patients regarding the removal rate and postsurgical residual tumor. All patients received standard adjuvant radiation and chemotherapy after surgery. We found the fusion image of preoperative Tl SPECT and postoperative MRI was more useful for evaluating glioma removal extent than just MRI. Patients with partial removal had a poor prognosis; thus, the aim should be for maximum surgical removal using multimodal images including MRI and Tl SPECT. The total removal of Tl

SPECT positive lesions improves the prognosis and prevents early recurrence(*18*).

Inflammation after surgery or radiation is a major cause of false positives(*3, 4, 19-21*). Other inflammatory lesions, like brain abscesses, can be also a source of a false positive scan(*22*) (**Figure 2**). Using combined Tl and ^{99m}Tc–hexamethylpropyleneamine oxime (Tc-HMPAO) for brain tumors has been recommended to increase the specificity of Tl SPECT (*2, 23*). Carvalho et al. assessed the ability of sequential Tl and Tc-HMPAO SPECT to distinguish tumor recurrence from radiation changes after high-dose radiation therapy for malignant gliomas. The authors found Tc-HMPAO SPECT is useful for identifying the absence of solid tumor recurrence in patients with low to moderate Tl uptake (ratio 1.1 to 3.4) and low perfusion to that site (less than 0.5.)(*23*).

Some causes of false negative findings may include small tumor size; located centrally or adjacent to areas of physiological tracer uptake, such as choroid plexus; histological heterogeneity; and cystic or necrotic components (*24, 25*).Young et al.(*25*) reported that when using a Tl-index > 2 in lesions bigger

than 2 cm, Tl SPECT has a 100% sensitivity and 89% specificity for the differentiation between brain lymphoma and toxoplasmosis in patients with AIDS; while, the sensitivity and specificity were 50% and 82%, respectively, in lesions smaller than 2 cm.

Both central neurocytomas and gangliogliomas are benign gliomas with a high Tl uptake (*26*)(*27*). High cell density and high metabolic rate are thought to explain the high Tl uptake in these low proliferative tumors. In our series, one patient with a central neurocytoma showed high Tl uptake and no Tc-MIBI uptake (**Figure 3**). In this case, Tc-MIBI SPECT was more accurate than Tl SPECT to evaluate tumor malignancy. Pilocytic astrocytoma is one of the most benign gliomas and the Tl SPECT findings show variable uptake (*28*). Lower Tl uptake is also observed in early follow-up studies after surgical excisions and/or aggressive chemotherapy. This is due to granulation tissue and new vascularity associated with treatment(*13*)

X-4-2 Tc-MIBI SPECT

Tc-MIBI is a lipophilic cationic complex with a physical half-life of 6 hours, initially designed for myocardial perfusion SPECT. Tc-MIBI SPECT is also useful to diagnose brain tumor recurrence (*29, 30*);evaluate the biological characteristics of brain tumors(*31*), tumor volume, and survival (*32, 33*); and in the differential diagnosis of radiation necrosis(*5*). As with Tl imaging, the Tc-MIBI index can be used to differentiate between low and high grade gliomas (*34*) as well as recurrence and radiation necrosis (*29*), and to estimate the prognosis (*32, 33*). Tc-MIBI is concentrated in the mitochondria as the result of active diffusion due to increased metabolic needs (*29*). Its uptake is affected by tumor malignancy, viability, density, oxygenation, vascular supply, and blood brain barrier (BBB) disruption (*35*). These factors are not linearly correlated because glioblastoma, the most malignant form of glioma, is pathologically heterogeneous and includes internal necrosis.

In Tc-MIBI SPECT, tumor imaging occurs approximately 20-30 minutes following injection of about 740 MBq Tc-MIBI.Delayed images (2-4 h p.i.) have been also recommended. The SPECT imaging should be done using a low energy general purpose collimator and the photopeak should be centered at 140

keV. In the brain, Tc-MIBI is taken up by normal choroid plexus, scalp, the pituitary gland, and nasopharyngeal tissues (*36*).

With respect to the histological type, a higher Tc-MIBI retention index has been noted in glioblastoma multiforme compared with metastatic tumors. In addition, while Tc-MIBI SPECT shows high uptake and retention in malignant gliomas, washout from metastatic brain tumors is faster than from glioblastomas(*37*).

Tc-MIBI has also been successfully used in high-grade gliomas to distinguish recurrent tumor from radionecrosis (*30*) and when the results of both CT and MRI are difficult to interpret, because of inflammation resulting from surgery or radiation, and offer only an imperfect indication of tumor viability(*38*). A false negative finding by MIBI SPECT may occur due to an intact BBB. (*30*). In a study on patients in the pre-surgical phase for interparenchymal brain tumors, Tc-MIBI SPECT identified tumors in the fronto-temporal regions more easily than in the temporal regions or in the posterior fossa (*36*). P-glycoprotein is a drug efflux pump in the cell membrane and it acts to remove Tc-MIBI from tumor cells (*40, 41*). Other studies have suggested that p-glycoprotein expression in malignant gliomas may cause false negative results in Tc-MIBI SPECT (*42-44*).However, the effect of p-glycoprotein expression on clinical Tc-MIBI

SPECT images has been investigated, and the effect was negligible in the diagnosis of brain tumor malignancy (*45*). Henze also reported that p-glycoprotein efflux does not contribute to falsely negative MIBI SPECT, since MIBI washout did not occur between the early and late SPECT scans (*46*).

Some of the false positive results were due to recent radiation induced local disruption of the BBB (*30*). Tc-MIBI shows early accumulation into the normal choroid plexus and good wash out from it. .Choroid plexus papillomas show slower tracer wash out than the normal choroid plexus;hence, the delayed MIBI index is higher than the early MIBI index(*47*).

X-4-2-1 Comparison of Tl and MIBI brain SPECT in patients with gliomas

The diagnostic values of brain Tl and Tc-MIBI SPECT have been evaluated by our group using sensitivities and specificities with arbitrary cut off values. The diagnostic ability of Tl SPECT and Tc-MIBI SPECT were directly compared for patients with an initial glioma using ROC analysis. The study population included 59 patients with gliomas. The benign group included patients with low grade astrocytomas and central neurocytomas; while,the malignant group included patients with anaplastic astrocytomas and glioblastomas. All patients

underwent Tl and Tc-MIBI SPECT and tumor/not-tumor (T/N) ratios were calculated. The area z-score(A_z) values were calculated from the areas under the ROC curves (**Figure 4**). The delayed Tc-MIBI had the highest A_z while the early MIBI had the lowest A_z. Both Tl and MIBI SPECT are considered useful imaging modalities for the evaluation of glioma malignancies. Delayed MIBI SPECT demonstrated better diagnostic value in patients with gliomas based on ROC analysis; although,the difference was not statistically significant(*48*).

Some studies have reported that Tc-MIBI SPECT has higher sensitivity and specificity than Tl SPECT for adult and childhood brain tumors and for the differential diagnosis of recurrence and radiation necrosis (*5, 33, 38*); however, other studies disagree(*37*). This discrepancy may be caused by small and heterogeneous patient populations and arbitrarily selected cut off values. In Tl SPECT, there is some normal brain uptake, which makes the T/N ratio low. Tc-MIBI has a high photon energy level and higher T/N ratio in comparison with Tl SPECT and yields clear SPECT images with high sensitivity for malignant brain tumors(*5, 29, 38*).

X-4-3 Tc-Tetrofosmin SPECT

TF is a lipophilic cationic tracer with a physical half-life of 6 hours that was initially used for myocardial perfusion SPECT. The utility of TF in evaluation of brain tumors has been demonstrated(*49-52*). Soricelli et al. (*49*) showed significant agreement among Tl and TF SPECT for the diagnosis of brain tumors; however, the image quality, contrast, and the definition of tumor margins obtained by TF were superior to those with Tl. TF is also useful for non-invasive grading. There was a striking difference between the TF index in low grade and high grade gliomas, which was not the case for Tl, Tc-MIBI, and 18F-FDG PET(*53*). TF can also distinguish tumor recurrence from radiation necrosis(*50-52*).We compared the radiological image findings from TF and Tl SPECT for 11 patients with brain tumors.The tracer uptakes of TF and Tl were almost matched. In the patients with meningioma, both TF and Tl early images showed high uptake and these tracers were washed out in delayed images (**Figure 5**). Both TF and Tl delayed SPECT images showed high uptake in tumors from patients with glioblastomas(**Figure 6**).

There is physiological TF uptake in the normal choroid plexus, which contributes to the spatial correlation between tumors and ventricles. TF SPECT is better and more useful than TI SPECT to diagnose tumor location, extent, malignancy, viability, and effects from therapies(*54*).

X-4-4:3-[123I]iodo-a-methyl-L-tyrosine SPECT

3-[123I]iodo-a-methyl-L-tyrosine (123I-IMT) is an amino acid SPECT tracer for brain imaging.Tumors are imaged with SPECT approximately 10 minutes after the injection of 370-740 MBq 123I-IMT. To prevent the uptake of free iodine, the thyroid should be blocked with 400-600 mg sodium perchlorate 30 minutes before tracer application. The SPECT imaging should be done using a low energy high resolution collimator using a 20% energy window centered on the 159-keV photopeak.123I-IMT SPECT was directly compared with [methyl-11C]-L-methionine (MET) PET in 14 patients with cerebral gliomas(*55*). Visual comparison of the scans yielded no differences in tumor size and shape with both methods. The tumor to brain ratios of 123I-IMT SPECT and MET PET showed a significant correlation especially in the early, transport dominated phase at 15 min after injection.

Kuwert et al.(*56*) showed that 123I-IMT SPECT may aid in differentiating high-grade gliomas from histologically benign brain tumors and non-neoplastic brain lesions; however, this modality was inappropriate for distinguishing non-neoplastic from benign lesions. In this study, the sensitivity and specificity of 123I-IMT SPECT were 71% and 83%, respectively, for differentiating high grade from low grade gliomas, 82% and 100%, respectively, for distinguishing high-grade gliomas from non-neoplastic lesions, and 50% and 100%, respectively, for discriminating low-grade gliomas from non-neoplastic lesions(*56*).

The utility of 123I-IMT SPECT for determining tumor grade and prognosis of the disease is controversial(*56-60*). A strong correlation between tracer uptake and tumor proliferative activity was reported by Kuwert etal.(*59*). In contrast,Weber et al.(*61*) reported that 123I-IMT uptake appeared not to correlate with the biological aggressiveness of tumor cells in patients with unresectable high-grade gliomas. Nevertheless, the clear association between focal 123I-IMT uptake after tumor resection and poor survival suggests that 123I-IMT is a specific marker for residual tumor tissue(*61*).

It is very important to precisely determine the tumor extent for planning surgery or radiation. 123I-IMT is taken up in brain areas with an intact blood-brain barrier and IMT SPECT appears to be able to image the infiltrating tissue of cerebral gliomas like MET(*62*).In a study using IMT SPECT in addition to MRI for planning radiation therapy, a larger tumor volume was detected by 123I-IMT SPECT than by conventional MRI. The authors highlighted that IMT-SPECT investigations improved tumor detection and delineation in the treatment planning process (*63*).

Several studies yielded good sensitivity and specificity of IMT SPECT for the detection of viable tumor tissue in previously treated patients (*57, 58, 64*). Bader et al. showed that 123I-IMT SPECT was equivalent to a stereotactic biopsy in its ability to identify high-grade tumors at recurrence (*57*).The fusion of 123I-IMT SPECT images with MRI improves the interpretation of the findings and may increase the specificity of the investigation(*65*). In addition, 123I-IMT-SPECT was a promising complementary imaging tool for the detection of recurrences of non-astrocytic intracranial tumors and for distinguishing them from treatment induced changes(*66*). Several studies indicate the utility of 123I-IMT in the follow-up of patients with brain tumors (*57, 64, 67*). Patients with

recurrence had significantly higher ratios of 123I-IMT   uptake in the tumor area

to that in the background region than patients without recurrence. The majority

of brain metastases exhibit high 123I-IMT uptake, which does not allow

differentiation from gliomas. A combination of 123I-IMT   and TI SPECT,

however, may be able to distinguish high-grade gliomas from other malignant

brain lesions, like metastases, with high accuracy (*68*).

References

1. Louis DN, Ohgaki H, Wiestler OD, et al. The 2007 WHO classification of tumours of the central nervous system. *Acta Neuropathol.* Aug 2007;114(2):97-109.

2. Schwartz RB, Carvalho PA, Alexander E, 3rd, Loeffler JS, Folkerth R, Holman BL. Radiation necrosis vs high-grade recurrent glioma: differentiation by using dual-isotope SPECT with 201Tl and 99mTc-HMPAO. *AJNR Am J Neuroradiol.* Nov-Dec 1991;12(6):1187-1192.

3. Yoshii Y, Satou M, Yamamoto T, et al. The role of thallium-201 single photon emission tomography in the investigation and characterisation of brain tumours in man and their response to treatment. *Eur J Nucl Med.* 1993;20(1):39-45.

4. Staffen W, Hondl N, Trinka E, Iglseder B, Unterrainer J, Ladurner G. Clinical relevance of 201Tl-chloride SPET in the differential diagnosis of brain tumours. *Nucl Med Commun.* Apr 1998;19(4):335-340.

5.   Yamamoto Y, Nishiyama Y, Toyama Y, Kunishio K, Satoh K, Ohkawa M. 99mTc-MIBI and 201Tl SPET in the detection of recurrent brain tumours after radiation therapy. *Nucl Med Commun.* 2002;23(12):1183-1190.

6.   Black KL, Hawkins RA, Kim KT, Becker DP, Lerner C, Marciano D. Use of thallium-201 SPECT to quantitate malignancy grade of gliomas. *J Neurosurg.* Sep 1989;71(3):342-346.

7.   O'Tuama LA, Janicek MJ, Barnes PD, et al. 201Tl/99mTc-HMPAO SPECT imaging of treated childhood brain tumors. *Pediatr Neurol.* Jul-Aug 1991;7(4):249-257.

8.   Sehweil A, McKillop JH, Ziada G, Al-Sayed M, Abdel-Dayem H, Omar YT. The optimum time for tumour imaging with thallium-201. *Eur J Nucl Med.* 1988;13(10):527-529.

9.   Sehweil AM, McKillop JH, Milroy R, Wilson R, Abdel-Dayem HM, Omar YT. Mechanism of 201Tl uptake in tumours. *Eur J Nucl Med.* 1989;15(7):376-379.

10.   Fukumoto M. Single-photon agents for tumor imaging: 201Tl, 99mTc-MIBI, and 99mTc-tetrofosmin. *Ann Nucl Med.* Apr 2004;18(2):79-95.

11.   Kosuda S, Shioyama Y, Kamata N, et al. [Differential diagnosis between recurrence of brain tumor and radiation necrosis by 201Tl SPECT]. *Nippon Igaku Hoshasen Gakkai Zasshi.* Apr 25 1991;51(4):415-421.

12.   Kosuda S, Fujii H, Aoki S, et al. Reassessment of quantitative thallium-201 brain SPECT for miscellaneous brain tumors. *Ann Nucl Med.* Nov 1993;7(4):257-263.

13.   Abdel Dayem H, Scott A, Macapinlac H. Thallium-201 chloride: a tumor imaging agent. In: Ell PJ, Gambhir S, eds. *Nuclear Medicine in clinical diagnosis and treatment.* Vol 1. 3 ed: Churchill Livinstone; 2004:71-81.

14.   Stathaki MI, Koukouraki SI, Karkavitsas NS. The role of scintigraphy in the evaluation of brain malignancies. *Hell J Nucl Med.* Sep-Dec 2010;13(3):264-272.

15. Ueda T, Kaji Y, Wakisaka S, et al. Time sequential single photon emission computed tomography studies in brain tumour using thallium-201. *Eur J Nucl Med.* Feb 1993;20(2):138-145.

16. Sugo N, Yokota K, Kondo K, et al. Early dynamic 201Tl SPECT in the evaluation of brain tumours. *Nucl Med Commun.* Feb 2006;27(2):143-149.

17. Kessler LS, Ruiz A, Donovan Post MJ, Ganz WI, Brandon AH, Foss JN. Thallium-201 brain SPECT of lymphoma in AIDS patients: pitfalls and technique optimization. *AJNR Am J Neuroradiol.* Jun-Jul 1998;19(6):1105-1109.

18. Shibata Y, Matsushita A, Akimoto M, et al. [Evaluation of surgical removal with fusion image of Tl SPECT and MRI] In Japanese. *CI research.* 2010;32(1):19-24.

19. Buchpiguel CA, Alavi JB, Alavi A, Kenyon LC. PET versus SPECT in distinguishing radiation necrosis from tumor recurrence in the brain. *J Nucl Med.* Jan 1995;36(1):159-164.

20.   Rollins NK, Lowry PA, Shapiro KN. Comparison of gadolinium-enhanced MR and thallium-201 single photon emission computed tomography in pediatric brain tumors. *Pediatr Neurosurg.* 1995;22(1):8-14.

21.   Serizawa T, Saeki N, Higuchi Y, et al. Diagnostic value of thallium-201 chloride single-photon emission computerized tomography in differentiating tumor recurrence from radiation injury after gamma knife surgery for metastatic brain tumors. *J Neurosurg.* 2005;102 Suppl:266-271.

22.   Martinez del Valle MD, Gomez-Rio M, Horcajadas A, et al. False positive thallium-201 SPECT imaging in brain abscess. *Br J Radiol.* Feb 2000;73(866):160-164.

23.   Carvalho PA, Schwartz RB, Alexander E, 3rd, et al. Detection of recurrent gliomas with quantitative thallium-201/technetium-99m HMPAO single-photon emission computerized tomography. *J Neurosurg.* Oct 1992;77(4):565-570.

24. Kallen K, Burtscher IM, Holtas S, Ryding E, Rosen I. 201Thallium SPECT and

1H-MRS compared with MRI in chemotherapy monitoring of high-grade malignant astrocytomas.

J Neurooncol. 2000;46(2):173-185.

25. Young RJ, Ghesani MV, Kagetsu NJ, Derogatis AJ. Lesion size determines

accuracy of thallium-201 brain single-photon emission tomography in differentiating between

intracranial malignancy and infection in AIDS patients. *AJNR Am J Neuroradiol.* Sep

2005;26(8):1973-1979.

26. Kumabe T, Shimizu H, Sonoda Y, Shirane R. Thallium-201 single-photon

emission computed tomographic and proton magnetic resonance spectroscopic characteristics

of intracranial ganglioglioma: three technical case reports. *Neurosurgery.* 1999;45(1):183-187.

27. Kanamori M, Kumabe T, Shimizu H, Yoshimoto T. (201)Tl-SPECT, (1)H-MRS,

and MIB-1 labeling index of central neurocytomas: three case reports. *Acta Neurochir (Wien).*

2002;144(2):157-163.

28. Comte F, Bauchet L, Rigau V, et al. Correlation of preoperative thallium SPECT with histological grading and overall survival in adult gliomas. *Nucl Med Commun.* 2006;27(2):137-142.

29. Soler C, Beauchesne P, Maatougui K, et al. Technetium-99m sestamibi brain single-photon emission tomography for detection of recurrent gliomas after radiation therapy. *Eur J Nucl Med.* Dec 1998;25(12):1649-1657.

30. Le Jeune FP, Dubois F, Blond S, Steinling M. Sestamibi technetium-99m brain single-photon emission computed tomography to identify recurrent glioma in adults: 201 studies. *J Neurooncol.* Apr 2006;77(2):177-183.

31. Ak I, Gulbas Z, Altinel F, Vardareli E. Tc-99m MIBI uptake and its relation to the proliferative potential of brain tumors. *Clin Nucl Med.* Jan 2003;28(1):29-33.

32. Beauchesne P, Soler C. Correlation of 99mTc-MIBI brain spect (functional index ratios) and survival after treatment failure in malignant glioma patients. *Anticancer Res.* Sep-Oct 2002;22(5):3081-3085.

33. Beauchesne P, Pedeux R, Boniol M, Soler C. 99mTc-sestamibi brain SPECT after chemoradiotherapy is prognostic of survival in patients with high-grade glioma. *J Nucl Med.* 2004;45(3):409-413.

34. Baillet G, Albuquerque L, Chen Q, Poisson M, Delattre JY. Evaluation of single-photon emission tomography imaging of supratentorial brain gliomas with technetium-99m sestamibi. *Eur J Nucl Med.* Oct 1994;21(10):1061-1066.

35. Henze M, Mohammed A, Schlemmer HP, et al. PET and SPECT for Detection of Tumor Progression in Irradiated Low-Grade Astrocytoma: A Receiver-Operating-Characteristic Analysis. *J Nucl Med.* April 1, 2004 2004;45(4):579-586.

36. Bagni B, Pinna L, Tamarozzi R, et al. SPET imaging of intracranial tumours with 99Tcm-sestamibi. *Nucl Med Commun.* Apr 1995;16(4):258-264.

37. Nishiyama Y, Yamamoto Y, Fukunaga K, Satoh K, Kunishio K, Ohkawa M. Comparison of 99Tcm-MIBI with 201Tl chloride SPET in patients with malignant brain tumours. *Nucl Med Commun.* Jun 2001;22(6):631-639.

38. O'Tuama LA, Treves ST, Larar JN, et al. Thallium-201 versus technetium-99m-MIBI SPECT in evaluation of childhood brain tumors: a within-subject comparison. *J Nucl Med.* Jul 1993;34(7):1045-1051.

39. Kirton A, Kloiber R, Rigel J, Wolff J. Evaluation of pediatric CNS malignancies with (99m)Tc-methoxyisobutylisonitrile SPECT. *J Nucl Med.* 2002;43(11):1438-1443.

40. Feun LG, Savaraj N, Landy HJ. Drug resistance in brain tumors. *J Neurooncol.* 1994;20(2)(0167-594X VI - 20 IP - 2 DP - 1994):165-176.

41. Lehnert M. Multidrug resistance in human cancer. *J Neurooncol.* 1994;22(3)(0167-594X VI - 22 IP - 3 DP - 1994):239-243.

42. Andrews DW, Das R, Kim S, Zhang J, Curtis M. Technetium-MIBI as a glioma imaging agent for the assessment of multi-drug resistance. *Neurosurgery.* 1997;40(6)(0148-396X VI - 40 IP - 6 DP - 1997 Jun):1323-1332.

43. Ballinger JR, Sheldon KM, Boxen I, Erlichman C, Ling V. Differences between accumulation of 99mTc-MIBI and 201Tl-thallous chloride in tumour cells: role of P-glycoprotein. *Q J Nucl Med.* 1995;39(2)(1124-3937 VI - 39 IP - 2 DP - 1995 Jun):122-128.

44. Piwnica-Worms D, Chiu ML, Budding M, Kronauge JF, Kramer RA, Croop JM. Functional imaging of multidrug-resistant P-glycoprotein with an organotechnetium complex. *Cancer Res.* 1993;53(5)(0008-5472 VI - 53 IP - 5 DP - 1993 Mar 1):977-984.

45. Shibata Y, Matsumura A, Nose T. Effect of expression of P-glycoprotein on technetium-99m methoxyisobutylisonitrile single photon emission computed tomography of brain tumors. *Neurol Med Chir (Tokyo).* 2002;42(8):325-330.

46.   Henze M, Mohammed A, Schlemmer H, et al. Detection of tumour progression in the follow-up of irradiated low-grade astrocytomas: comparison of 3-[123I]iodo-alpha-methyl-L-tyrosine and 99mTc-MIBI SPET. *Eur J Nucl Med Mol Imaging.* 2002;29(11):1455-1461.

47.   Shibata Y, Katayama W, Kawamura H, Anno I, Matsumura A. Proton Magnetic Resonance Spectroscopy and 201Thallium-, 99m Technetium methoxyisobutylisonitrile Single Photon Emission Computed Tomography findings of a patient with choroids plexus papilloma. *Neuroradiology.* 2008;50(8):741-742.

48.   Shibata Y, Yamamoto T, Takano S, Katayama W, Takeda T, Matsumura A. Direct comparison of thallium-201 and technetium-99m MIBI SPECT of a glioma by receiver operating characteristic analysis. *J Clin Neurosci.* Feb 2009;16(2):264-269.

49.   Soricelli A, Cuocolo A, Varrone A, et al. Technetium-99m-tetrofosmin uptake in brain tumors by SPECT: comparison with thallium-201 imaging. *J Nucl Med.* May 1998;39(5):802-806.

50. Alexiou GA, Tsiouris S, Goussia A, et al. Evaluation of glioma proliferation by 99mTc-Tetrofosmin. *Neuro-oncology.* Feb 2008;10(1):104-105.

51. Alexiou GA, Tsiouris S, Kyritsis AP, Polyzoidis KS, Fotopoulos AD. Classic tumour imaging agents for glioma evaluation: 99mTc-tetrofosmin. *Eur J Nucl Med Mol Imaging.* Dec 2007;34(12):2143-2144.

52. Alexiou GA, Fotopoulos AD, Papadopoulos A, Kyritsis AP, Polyzoidis KS, Tsiouris S. Evaluation of brain tumor recurrence by (99m)Tc-tetrofosmin SPECT: a prospective pilot study. *Ann Nucl Med.* Jul 2007;21(5):293-298.

53. Choi JY, Kim SE, Shin HJ, Kim BT, Kim JH. Brain tumor imaging with 99mTc-tetrofosmin: comparison with 201Tl, 99mTc-MIBI, and 18F-fluorodeoxyglucose. *J Neurooncol.* 2000;46(1):63-70.

54. Shibata Y, Endo K. [Evaluation of brain tumos with Tc-Tetrofosmin SPECT] In Japanese. *CI research.* 2011;33:175-180.

55. Langen KJ, Ziemons K, Kiwit JC, et al. 3-[123I]iodo-alpha-methyltyrosine and [methyl-11C]-L-methionine uptake in cerebral gliomas: a comparative study using SPECT and PET. *J Nucl Med.* Apr 1997;38(4):517-522.

56. Kuwert T, Morgenroth C, Woesler B, et al. Uptake of iodine-123-alpha-methyl tyrosine by gliomas and non-neoplastic brain lesions. *Eur J Nucl Med.* Oct 1996;23(10):1345-1353.

57. Bader JB, Samnick S, Moringlane JR, et al. Evaluation of l-3-[123I]iodo-alpha-methyltyrosine SPET and [18F]fluorodeoxyglucose PET in the detection and grading of recurrences in patients pretreated for gliomas at follow-up: a comparative study with stereotactic biopsy. *Eur J Nucl Med.* Feb 1999;26(2):144-151.

58. Kuwert T, Probst-Cousin S, Woesler B, et al. Iodine-123-alpha-methyl tyrosine in gliomas: correlation with cellular density and proliferative activity. *J Nucl Med.* Oct 1997;38(10):1551-1555.

59. Woesler B, Kuwert T, Morgenroth C, et al. Non-invasive grading of primary brain tumours: results of a comparative study between SPET with 123I-alpha-methyl tyrosine and PET with 18F-deoxyglucose. *Eur J Nucl Med.* Apr 1997;24(4):428-434.

60. Weber W, Bartenstein P, Gross MW, et al. Fluorine-18-FDG PET and iodine-123-IMT SPECT in the evaluation of brain tumors. *J Nucl Med.* May 1997;38(5):802-808.

61. Weber WA, Dick S, Reidl G, et al. Correlation between postoperative 3-[(123)I]iodo-L-alpha-methyltyrosine uptake and survival in patients with gliomas. *J Nucl Med.* Aug 2001;42(8):1144-1150.

62. Langen KJ, Pauleit D, Coenen HH. 3-[(123)I]Iodo-alpha-methyl-L-tyrosine: uptake mechanisms and clinical applications. *Nucl Med Biol.* Aug 2002;29(6):625-631.

63. Grosu AL, Weber W, Feldmann HJ, et al. First experience with I-123-alpha-methyl-tyrosine spect in the 3-D radiation treatment planning of brain gliomas. *Int J Radiat Oncol Biol Phys.* May 1 2000;47(2):517-526.

64. Guth-Tougelidis B, Muller S, Mehdorn MM, Knust EJ, Dutschka K, Reiners C. [Uptake of DL-3-123I-iodo-alpha-methyltyrosine in recurrent brain tumors]. *Nuklearmedizin.* Apr 1995;34(2):71-75.

65. Amthauer H, Wurm R, Kuczer D, et al. Relevance of image fusion with MRI for the interpretation of I-123 iodo-methyl-tyrosine scans in patients with suspected recurrent or residual brain tumor. *Clin Nucl Med.* Apr 2006;31(4):189-192.

66. Plotkin M, Eisenacher J, Bruhn H, et al. 123I-IMT SPECT and 1H MR-spectroscopy at 3.0 T in the differential diagnosis of recurrent or residual gliomas: a comparative study. *J Neurooncol.* Oct 2004;70(1):49-58.

67. Kuwert T, Woesler B, Morgenroth C, et al. Diagnosis of recurrent glioma with SPECT and iodine-123-alpha-methyl tyrosine. *J Nucl Med.* Jan 1998;39(1):23-27.

68. Matheja P, Rickert C, Weckesser M, et al. Sequential scintigraphic strategy for the differentiation of brain tumours. *Eur J Nucl Med.* May 2000;27(5):550-558.